Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Long-Term Investments (2020 - 2021)

Ensysce Biosciences (ENSC) has disclosed Long-Term Investments for 2 consecutive years, with $12.7 million as the latest value for Q1 2021.

  • On a quarterly basis, Long-Term Investments fell 79.31% to $12.7 million in Q1 2021 year-over-year; TTM through Mar 2021 was $12.7 million, a 79.31% decrease, with the full-year FY2020 number at $12.6 million, changed N/A from a year prior.
  • Long-Term Investments was $12.7 million for Q1 2021 at Ensysce Biosciences, roughly flat from $12.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $61.3 million in Q1 2020 to a low of $53492.0 in Q3 2020.